Nuclear imaging with SPECT or PET tracers has the potential to play a crucial role in the early and differential diagnosis of AD, in the follow up of longitudinal progression and to support the development of novel therapeutic approaches, by visualizing the Tau deposits in vivo, by providing information on the regional distribution and the spatiotemporal evolution of the disease [46]. Here, MAPT is linked to Alzheimer disease.